Quince Therapeutics (QNCX) EBT (2018 - 2026)
Quince Therapeutics (QNCX) posted quarterly EBT of $30.6 million for Q1 2026, up 304.05% year-over-year from $7.6 million in Q1 2025, and up 184.2% quarter-over-quarter from -$36.3 million in Q4 2025.
Quince Therapeutics (QNCX) EBT (2018 - 2026) Analysis & Trends
Quince Therapeutics' EBT history runs 9 years deep, the most recent figure standing at $30.6 million for Q1 2026.
- In Q1 2026, EBT rose 304.05% year-over-year to $30.6 million; the TTM figure through Mar 2026 stood at -$35.2 million (up 41.91% YoY), while the FY2025 annual figure was -$80.8 million, down 42.34% from the prior year.
- EBT for Q1 2026 stood at $30.6 million, up from -$36.3 million in the prior quarter.
- The five-year high for EBT was $30.6 million in Q1 2026, with the low at -$36.3 million in Q4 2025.
- The 5-year median for EBT is -$12.5 million (2024), against an average of -$11.2 million.
- The sharpest annual moves came in 2024 and 2026: EBT plunged 466.78% in 2024, then surged 304.05% in 2026.
- Quince Therapeutics' EBT stood at -$5.5 million in 2022, then tumbled by 59.79% to -$8.8 million in 2023, then slumped by 40.8% to -$12.5 million in 2024, then plunged by 191.64% to -$36.3 million in 2025, then surged by 184.2% to $30.6 million in 2026.
- Business Quant data shows QNCX's EBT at $30.6 million in Q1 2026, -$36.3 million in Q4 2025, and -$13.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 177.81 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -264.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -11.37 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | -75.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.57 Mn |
| Dec 31, 2025 | -36.31 Mn |
| Sep 30, 2025 | -13.49 Mn |
| Jun 30, 2025 | -15.98 Mn |
| Mar 31, 2025 | -14.98 Mn |
| Dec 31, 2024 | -12.45 Mn |
| Sep 30, 2024 | -5.48 Mn |
| Jun 30, 2024 | -27.69 Mn |
| Mar 31, 2024 | -11.12 Mn |
| Dec 31, 2023 | -8.84 Mn |
| Sep 30, 2023 | -5.35 Mn |
| Jun 30, 2023 | -4.89 Mn |
| Mar 31, 2023 | -12.50 Mn |
| Dec 31, 2022 | -5.53 Mn |
| Sep 30, 2022 | -7.92 Mn |
| Jun 30, 2022 | -16.85 Mn |
| Mar 31, 2022 | -21.64 Mn |
| Dec 31, 2021 | 66.55 Mn |
| Sep 30, 2021 | -21.71 Mn |
| Jun 30, 2021 | -21.75 Mn |